Cannabidiol inhibits SARS-Cov-2 spike (S) protein-induced cytotoxicity and inflammation through a PPARγ-dependent TLR4/NLRP3/Caspase-1 signaling suppression in Caco-2 cell line.
Caco-2
Cannabidiol
NLRP3
SARS-CoV-2 spike (S) protein
Journal
Phytotherapy research : PTR
ISSN: 1099-1573
Titre abrégé: Phytother Res
Pays: England
ID NLM: 8904486
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
15
09
2021
received:
16
06
2021
accepted:
19
09
2021
pubmed:
14
10
2021
medline:
25
12
2021
entrez:
13
10
2021
Statut:
ppublish
Résumé
Given the abundancy of angiotensin converting enzyme 2 (ACE-2) receptors density, beyond the lung, the intestine is considered as an alternative site of infection and replication for severe acute respiratory syndrome by coronavirus type 2 (SARS-CoV-2). Cannabidiol (CBD) has recently been proposed in the management of coronavirus disease 2019 (COVID-19) respiratory symptoms because of its anti-inflammatory and immunomodulatory activity exerted in the lung. In this study, we demonstrated the in vitro PPAR-γ-dependent efficacy of CBD (10
Identifiants
pubmed: 34643000
doi: 10.1002/ptr.7302
pmc: PMC8662250
doi:
Substances chimiques
Cytokines
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
PPAR gamma
0
Spike Glycoprotein, Coronavirus
0
TLR4 protein, human
0
Toll-Like Receptor 4
0
spike protein, SARS-CoV-2
0
Cannabidiol
19GBJ60SN5
Caspase 1
EC 3.4.22.36
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6893-6903Informations de copyright
© 2021 The Authors. Phytotherapy Research published by John Wiley & Sons Ltd.
Références
Front Pharmacol. 2021 Apr 28;12:641210
pubmed: 33995048
Adv Drug Deliv Rev. 2021 Mar;170:1-25
pubmed: 33359141
Sci Rep. 2021 Jan 14;11(1):1462
pubmed: 33446817
Br J Pharmacol. 2020 Nov;177(21):4967-4970
pubmed: 32519753
J Cell Mol Med. 2020 Nov;24(21):12869-12872
pubmed: 33058425
Immunobiology. 2010 Aug;215(8):611-6
pubmed: 19833407
Immunotargets Ther. 2020 Aug 18;9:131-140
pubmed: 32903924
J Med Chem. 2020 Nov 12;63(21):12137-12155
pubmed: 32804502
Infect Immun. 1998 Jun;66(6):2410-9
pubmed: 9596696
J Pharmacol Exp Ther. 2021 May;377(2):273-283
pubmed: 33658314
Inflammation. 2019 Dec;42(6):2215-2225
pubmed: 31473900
Br J Clin Pharmacol. 2019 Sep;85(9):1888-1900
pubmed: 31222854
FASEB J. 2020 Nov;34(11):14083-14092
pubmed: 32885502
Int J Mol Sci. 2019 Jul 06;20(13):
pubmed: 31284572
Phytother Res. 2016 Jun;30(6):963-70
pubmed: 26929026
Nat Rev Gastroenterol Hepatol. 2020 Jul;17(7):383
pubmed: 32427981
Nat Immunol. 2016 Aug;17(8):914-21
pubmed: 27270401
Metabolites. 2021 Sep 02;11(9):
pubmed: 34564408
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Pharmacol Ther. 2010 Apr;126(1):21-38
pubmed: 20117132
Cell Res. 2021 Jul;31(7):818-820
pubmed: 33742149
Theranostics. 2021 Jan 1;11(5):2424-2441
pubmed: 33500734
Front Pharmacol. 2020 Nov 06;11:589438
pubmed: 33240092
Dig Dis Sci. 2020 Jul;65(7):1932-1939
pubmed: 32447742
Clin Infect Dis. 2021 Nov 2;73(9):e2814-e2817
pubmed: 33086379
PLoS One. 2011;6(12):e28159
pubmed: 22163000
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Virus Res. 2020 Sep;286:198103
pubmed: 32717345
J Immunol. 2020 Jun 15;204(12):3339-3350
pubmed: 32385136
United European Gastroenterol J. 2017 Dec;5(8):1108-1115
pubmed: 29238589
J Med Virol. 2021 Jan;93(1):61-63
pubmed: 32492199
Stroke. 2005 May;36(5):1077-82
pubmed: 15845890
Cannabis Cannabinoid Res. 2020 Sep 02;5(3):197-201
pubmed: 32923657
Front Pharmacol. 2021 Apr 12;12:631646
pubmed: 33912048
Eur J Pharmacol. 2012 Mar 5;678(1-3):78-85
pubmed: 22265864
Int J Mol Sci. 2021 Feb 17;22(4):
pubmed: 33671463
Phytother Res. 2021 Dec;35(12):6893-6903
pubmed: 34643000
J Pharmacol Exp Ther. 2010 Oct;335(1):92-102
pubmed: 20592049
Brain Behav Immun. 2020 Jul;87:93-94
pubmed: 32335192
Dig Dis Sci. 2021 Oct;66(10):3228-3230
pubmed: 33428034